CALGARY, AB: KASTx Ventures, a biotechnology-focused venture capital firm and accelerator, welcomes Jeff Miller as Partner. Miller is the first American to join the KASTx team, and will set up the KASTx US-based operations in the Northeast. He has over 25 years of leadership experience in the biopharmaceutical industry working for globally recognized companies such as Alnylam, Alexion, Boehringer Ingelheim, Eli Lilly, and Merck Serono. Over that time, he has held a number of roles in Canada, as the founding General Manager of Alnylam Canada, and Head of Marketing, Market Research, and Oncology with Boehringer Ingelheim Canada. His career has taken him around the world, working in over 20 different countries, bringing a truly global network to KASTx.
Most recently, he has helped advise numerous biotechnology companies, specializing in corporate and capitalization strategy. The KASTx Ventures team has previously worked with Miller through their shared connections in the early-stage biotechnology space.
“Jeff has proven himself to be an incredibly valuable leader from the moment we crossed paths with him,” said Mark Starratt, KASTx Ventures Managing Partner. “We are thrilled to have him join our team, and we know his decades of global leadership experience will be significant in helping to grow the reach of our portfolio companies.”
As a Partner at KASTx Ventures, Jeff will be taking a hands-on role as an operational leader and advisor, working to accelerate the company’s rapidly growing ventures.
“I am thrilled to be joining the KASTx Ventures team,” Miller said. “This is a formidable team of scientific, research, medical, and business experts, and I’m committed to help bring these potentially life changing technologies and treatments to the people around the world that need them most.”
Learn more about Jeff and the KASTx Ventures team
KASTx Ventures brings together experienced, values-based leaders who are recognized experts in their field with proven skills to maximize a company’s impact. Our mission is to rapidly commercialize top science into globally impactful ventures.
